Perjeta Injection, Solution, Concentrate
NDC Package 50242-145-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Perjeta (pertuzumab) injection is pertuzumab is used to treat certain types of breast cancer. This formulation utilizes a injection, solution, concentrate delivery system. Marketed by Genentech, Inc., this product is identified by NDC 50242-145 and is authorized under FDA application BLA125409.

Identification & Billing

NDC Package Code
50242-145-01
Package Description
1 VIAL, SINGLE-USE in 1 CARTON / 14 mL in 1 VIAL, SINGLE-USE
Product Code
50242-145
11-Digit Billing Format
50242014501
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Perjeta
Non-Proprietary Name
Pertuzumab
Substance Name
Pertuzumab
Dosage Form
Injection, Solution, Concentrate - A sterile preparation for parenteral use which, upon the addition of suitable solvents, yields a solution conforming in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
PERTUZUMAB 30 mg/mL
Pharmacologic Class
Usage Information
Pertuzumab is used to treat certain types of breast cancer. It is also used to treat early stage breast cancer in patients who will be having surgery to remove the cancer. The types of cancers pertuzumab is used to treat are tumors that produce more than the normal amount of a certain substance called HER2 protein. This medication is called a monoclonal antibody. It works by attaching to the HER2 cancer cells and blocking them from dividing and growing. It may also destroy the cancer cells or signal the body (immune system) to destroy the cancer cells.

Regulatory & Marketing

Labeler Name
Genentech, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA125409
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
06-08-2012
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J9306
Source: ASP
Injection, pertuzumab, 1 mg
HCPCS Dosage 1 MG
Units / Pkg 420

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50242-145-01 identifies a specific commercial package of 1 vial, single-use in 1 carton / 14 ml in 1 vial, single-use of Perjeta, a human prescription drug labeled by Genentech, Inc.. This injection, solution, concentrate is formulated for intravenous use and contains pertuzumab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Genentech, Inc. on June 08, 2012. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Pertuzumab is used to treat certain types of breast cancer. It is also used to treat early stage breast cancer in patients who will be having surgery to remove the cancer. The types of cancers pertuzumab is used to treat are tumors that produce more than the normal amount of a certain substance called HER2 protein. This medication is called a monoclonal antibody. It works by attaching to the HER2 cancer cells and blocking them from dividing and growing. It may also destroy the cancer cells or signal the body (immune system) to destroy the cancer cells.

How is this Genentech, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50242014501. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
50242-145-01
11-Digit CMS (5-4-2)
50242-0145-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.